NLM Digital Collections

Search

Search Constraints

Start Over You searched for: Subjects United States. Food and Drug Administration. Remove constraint Subjects: United States. Food and Drug Administration. Languages English Remove constraint Languages: English

Search Results

271. Pediatric HIV infection: drug product development for treatment

272. Human immunodeficiency virus-1 infection: developing systemic drug products for pre-exposure prophylaxis

273. Interpretation of and compliance policy for certain label requirement: applicability of certain Federal Food, Drug, and Cosmetic Act requirements to vape shops

274. Standards development and the use of standards in regulatory submissions reviewed in the Center for Biologics Evaluation and Research

275. Pediatric information incorporated into human prescription drug and biological product labeling

276. Recommended content and format of non-clinical bench performance testing information in premarket submissions: guidance for industry and Food and Drug Administration staff

277. Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment

278. REMS: FDA's application of statutory factors in determining when a REMS is necessary

279. Extending expiration dates of doxycycline tablets and capsules in strategic stockpiles: guidance for government public health and emergency response stakeholders

280. Class II special controls guideline: in vitro diagnostic devices for Bacillus spp. detection : guideline for industry and Food and Drug Administration staff